Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 2/20 | 0.34 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.34 |
| ▸ | SHBG | P04278 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8190656 | 1.00 | ANPEP (0.34) | ANPEPENPEPSHBG | |
| SCHEMBL7608856 | 0.89 | — | — | |
| SCHEMBL8943205 | 0.81 | CPB2 (0.36) | ANPEPENPEP | |
| SCHEMBL2640244 | 0.81 | CPB2 (0.36) | ANPEPENPEP | |
| SCHEMBL7375737 | 0.80 | ALOX5 (0.34) | — | |
| SCHEMBL7375837 | 0.80 | — | — | |
| SCHEMBL7418539 | 0.78 | METAP1 (0.37) | — | |
| SCHEMBL1449256 | 0.78 | METAP1 (0.37) | — | |
| SCHEMBL3504941 | 0.78 | METAP1 (0.37) | — | |
| SCHEMBL10583764 | 0.75 | CPN1 (0.42) | ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5449612-A | Process for identifying candida by means of chromogenic substances | SERBIO (FR) | 1995-09-12 | — | — | US | claimed |
| EP-0280610-B1 | DIPEPTIDES, PREPARATION PROCESS AND USE IN DOSING PROTEASES | SERBIO (FR) | 1992-10-21 | — | — | EP | claimed |
| EP-1545572-A4 | CONJUGATES ACTIVATED BY CELL SURFACE PROTEASES AND THERAPEUTIC USES THEREOF | DENDREON CORP (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1545572-A2 | CONJUGATES ACTIVATED BY CELL SURFACE PROTEASES AND THERAPEUTIC USES THEREOF | Dendreon Corporation (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040001801-A1 | Conjugates activated by cell surface proteases and therapeutic uses thereof | CORVAS INTERNATIONAL, INC. | 2004-01-01 | — | — | US | disclosed |
| WO-2002095007-A2 | CONJUGATES ACTIVATED BY CELL SURFACE PROTEASES AND THERAPEUTIC USES THEREOF | DENDREON SAN DIEGO LLC (US) | 2002-11-28 | — | — | WO | disclosed |
| US-6121239-A | SPECIFIED TRI- AND TETRA-PEPTIDES | SERBIO (FR) | 2000-09-19 | — | — | US | disclosed |
| EP-0456567-B1 | Procedure to determine a plasminogen activator and its inhibitor | STAGO DIAGNOSTICA (FR) | 1998-01-07 | — | — | EP | disclosed |
| EP-0476107-B1 | PROCESS FOR IDENTIFYING CANDIDA ALBICANS BY MEANS OF CHROMOGENIC SUBSTANCES | STAGO DIAGNOSTICA (FR) | 1996-06-19 | — | — | EP | disclosed |
| US-5472851-A | Converting plasminogen to plasmin and the assaying plasmin resulting from said conversion; inhibiting plsma proteins alpha2-antiplsmin and alpha2-macroglobulin by contact with metalloproteinase | SERBIO (FR) | 1995-12-05 | — | — | US | disclosed |
| US-5449612-A | Process for identifying candida by means of chromogenic substances | SERBIO (FR) | 1995-09-12 | — | — | US | disclosed |
| US-5225532-A | SYMMETRICAL BIPEPTIDES CONTAINING A POLYALKYLENE GLYCOL RESIDUE, METHOD OF PREPARATION AND USE IN THE ASSAY OF PROTEASES | SERBIO (FR) | 1993-07-06 | — | — | US | disclosed |
| EP-0280610-B1 | DIPEPTIDES, PREPARATION PROCESS AND USE IN DOSING PROTEASES | SERBIO (FR) | 1992-10-21 | — | — | EP | disclosed |
| EP-0472671-A1 | PEPTIDE SUBSTRATES FOR Xa FACTOR IDENTIFICATION. | SERBIO (FR) | 1992-03-04 | — | — | EP | disclosed |
| EP-0456567-A1 | Procedure to determine a plasminogen activator and its inhibitor | DIAGNOSTICA STAGO (société anonyme) (FR) | 1991-11-13 | — | — | EP | disclosed |
| WO-1991014787-A1 | PROCESS FOR IDENTIFYING CANDIDA BY MEANS OF CHROMOGENIC SUBSTANCES | SERBIO (FR) | 1991-10-03 | — | — | WO | disclosed |
| WO-1991012338-A1 | PEPTIDE SUBSTRATES FOR Xa FACTOR IDENTIFICATION | SERBIO (FR) | 1991-08-22 | — | — | WO | disclosed |
| WO-1991012263-A1 | SYMMETRICAL BIPEPTIDES INCLUDING A POLYALKYLENE-GYLCOL GROUP, METHOD OF PREPARATION AND USE IN PROTEASE DETERMINATION | SERBIO (FR) | 1991-08-22 | — | — | WO | disclosed |
| EP-0280610-A1 | Dipeptides, preparation process and use in dosing proteases | SERBIO (FR) | 1988-08-31 | — | — | EP | disclosed |
| US-4598043-A | Method for quantitatively assaying blood coagulation factor XII in human plasma | PENTAPHARM AG (CH) | 1986-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040001801-A1 | Conjugates activated by cell surface proteases and therapeutic uses thereof | PLAUR, ENPEP, MASP2 | ANPEP 54/4885ENPEP 2/4885SHBG 2312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.